Vaxcyte
PCVX · NASDAQ
Bulios Fair Price
$50.7
14.0% downside
Current Price
$58.92
According to Bulios Fair Price, PCVX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Vaxcyte is an American biotechnology company focused on developing vaccines for the prevention of serious infectious diseases. The company specializes in advanced vaccine technologies, including cellular therapies and protein-based vaccines, with the aim of providing effective protection against pathogens that currently lack sufficient vaccines. Vaxcyte is developing vaccines for infections such as pneumococcal disease and is working to improve immunization and the prevention of infectious diseases globally.
Sector
Healthcare
Industry
Biotechnology
CEO
Grant E. Pickering
Employees
507
Headquarters
San Carlos
Upcoming events
Earnings
Upcoming earnings report